Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Oct;17(10):1024-1025.
doi: 10.1038/s41423-020-0512-x. Epub 2020 Jul 29.

The other side of the innate immune system: humoral arms favoring cancer

Maria De Santis  1 , Alberto Mantovani  2   3   4 , Carlo Selmi  5   6
Affiliations
Comment

The other side of the innate immune system: humoral arms favoring cancer

Maria De Santis et al. Cell Mol Immunol. 2020 Oct.

Abstract

Cancer cells take advantage of NETosis to escape host immune surveillance and mediate metastasis. The pharmacological targeting of NETosis may prove beneficial in maximizing the response to cancer immunotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
A schematic representation of neutrophil recruitment, NET formation and resistance to innate and adaptive lymphoid cell-mediated immune responses in primary and metastatic cancer
See this image and copyright information in PMC

Comment on

References

    1. Teijeira A, et al. CXCR1 and CXCR2 chemokine receptor agonists produced by tumors induce neutrophil extracellular traps that interfere with immune cytotoxicity. Immunity. 2020;52:856–71 e8. doi: 10.1016/j.immuni.2020.03.001. - DOI - PubMed
    1. Koch J, Tesar M. Recombinant antibodies to arm cytotoxic lymphocytes in cancer immunotherapy. Transfus. Med Hemother. 2017;44:337–350. doi: 10.1159/000479981. - DOI - PMC - PubMed
    1. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev. Immunol. 2004;22:329–360. doi: 10.1146/annurev.immunol.22.012703.104803. - DOI - PubMed
    1. Masuda S, et al. NETosis markers: quest for specific, objective, and quantitative markers. Clin. Chim. Acta. 2016;459:89–93. doi: 10.1016/j.cca.2016.05.029. - DOI - PubMed
    1. Jaillon, S. et al. Neutrophil diversity and plasticity in tumour progression and therapy. Nat. Rev. Cancer. 2020. In press. 10.1038/s41568-020-0281-y. - PubMed

Substances